Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Atorvastatin/ezetimibe - Merck & Co

Drug Profile

Atorvastatin/ezetimibe - Merck & Co

Alternative Names: Ateroclar Combi; Atozet; Atozet Combination Tablets HD; Atozet Combination Tablets LD; Colmibe; Ezetimibe/atorvastatin; Kexrolt; Liptruzet; MK-0653c; Orvatez; SCH-900068; Sersemic; Tioblis; Zardiux; Zoletorv

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck/Schering-Plough Pharmaceuticals
  • Developer Merck & Co; Rovi
  • Class Amides; Antihyperlipidaemics; Azetidines; Fatty acids; Fluorobenzenes; Heptanoic acids; Propanols; Pyrroles
  • Mechanism of Action Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors; NPC1L1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypercholesterolaemia; Hyperlipidaemia

Most Recent Events

  • 27 May 2019 Phase-III clinical trials in Hypercholesterolaemia (Adjunctive treatment) in China (PO) (NCT03768427)
  • 27 Dec 2018 Chemical structure information added
  • 07 Dec 2018 Merck Sharp & Dohme Corp plans a phase III trial for Hypercholesterolaemia (Second line or greater therapy) in China (NCT03768427)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top